Diagnostic Biochips

Executive Summary

Diagnostic Biochips is a Baltimore-based neuroscience medical device company developing the SomaFocus platform, a high-resolution electrophysiology system that captures real-time, circuit-level neural activity from intact 3D brain organoids. The technology addresses a critical gap in preclinical drug development by providing functional readouts without the need for extensive tissue preparation, enabling more accurate disease modeling and therapeutic screening for neurological disorders. Currently at the pre-clinical stage, the company is positioning itself as a key enabler for pharmaceutical companies seeking to de-risk CNS drug candidates through more predictive organoid-based assays. The company's differentiation lies in its ability to record from intact organoids at single-cell resolution, offering a significant improvement over traditional patch-clamp or multi-electrode arrays. With increasing adoption of organoids in drug discovery, Diagnostic Biochips is well-timed to capture market interest. Key challenges include scaling manufacturing, validating the platform across multiple disease models, and securing partnerships for co-development. The company's progress will depend on demonstrating reproducibility and utility in industry-standard screens, as well as raising sufficient capital to advance toward commercial readiness.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round to Scale Platform Development70% success
• Q4 2026Publication of Validation Data in Peer-Reviewed Journal80% success
• Q2 2027Pharma Partnership for Therapeutic Screening50% success